Andreas Argyrides

Andreas Argyrides is a Senior Equity Research Analyst at Chardan focused on high-growth SMid-cap companies in the biotechnology sector. Mr. Argyrides brings nearly two decades of experience spanning Wall Street equity research and healthcare investing and is based in Chardan's New York office.

Prior to joining Chardan, Mr. Argyrides served as Managing Director and Senior Equity Research Analyst at Oppenheimer & Co. Inc., where he led coverage of companies across the respiratory, immunology and inflammation (I&I), and rare disease therapeutic sectors. Previously, he covered the emerging pharmaceuticals sector at Wedbush PacGrow, focusing on innovative platform delivery technologies in ophthalmology, liver and pulmonary diseases, small molecules for metabolic and endocrine disorders, and gene therapies targeting rare genomic diseases.

Earlier in his career, Mr. Argyrides spent a decade in healthcare and investment roles, including serving as a healthcare sector specialist and research analyst at a long/short biotech-focused hedge fund. His background combines deep sector expertise with extensive experience evaluating emerging biotechnology companies and therapeutic innovations.